



OPEN Prescription of vitamin D was associated with a lower incidence of hip fractures

Mitsutaka Yakabe¹, Tatsuya Hosoi¹, Shoya Matsumoto¹, Kenji Fujimori^{2,8}, Junko Tamaki^{3,8}, Shinichi Nakatoh^{4,8}, Shigeyuki Ishii^{5,8}, Nobukazu Okimoto^{6,8}, Kuniyasu Kamiya^{3,8}, Masahiro Akishita¹, Masayuki Iki^{7,8} & Sumito Ogawa^{1,8}✉

Patients with osteoporosis are prone to fragility fractures. Evidence of the effects of active forms of vitamin D on hip fracture prevention is insufficient. We examined the association between vitamin D prescription and incidence of new fractures using the data of osteoporotic patients from the nationwide health insurance claims database of Japan. The follow-up period was 3 years after entry. The untreated patients were never prescribed vitamin D during follow-up ($n = 422,454$), and the treated patients had a vitamin D medication possession ratio of ≥ 0.5 at all time points ($n = 169,774$). Propensity score matching was implemented on these groups, yielding 105,041 pairs, and subsequently, the control and treatment groups were established and analyzed. The incidence of new fractures was significantly lower in the treatment group compared with the control group (6.25% vs. 5.69%, hazard ratio 0.936 [95% confidence interval 0.904–0.970], $p < 0.001^*$). By site, hip fractures significantly decreased (0.89% vs. 0.42%, $p < 0.001$), but not vertebral and radial fractures. Subgroup analysis by vitamin D type showed a significantly lower incidence of total fractures only in alfacalcidol (hazard ratio 0.676 [95% confidence interval 0.628–0.728], $p < 0.001^*$). The results suggest that vitamin D prescription was associated with a reduced incidence of hip fractures.

Osteoporosis is a systemic skeletal disease involving bone tissues, leading to bone fragility and susceptibility to fracture¹. As the world population ages, the number of patients with osteoporosis and resulting fractures is expected to increase².

Studies have reported that 98% of hip fractures³ and 100% of wrist fractures were caused by falls⁴. Age-related sarcopenia, frailty, physical deterioration, and various concomitant diseases increase the risk of falls, which may lead to fractures. Fractures are associated with disability, lower quality of life, and increased risk of refractures and mortality in older people^{5–7}. Older women who have experienced initial fractures are at high risk of early and subsequent fractures⁸. Mortality after a hip fracture is very high compared with the general population, with 32.7% of patients dying within 2 years following fracture onset, with pneumonia and circulatory diseases as the most common causes of death⁹. Therefore, osteoporosis treatment and fall prevention are important to prevent fractures in older people.

Vitamin D is used to treat osteoporosis, and activated vitamin D has been reported to increase bone mineral density (BMD)^{10,11}. A meta-analysis showed that low serum 25(OH)D level is associated with a higher risk of hip fracture in older people¹². A systematic umbrella review of meta-analyses of controlled trials of the effects of vitamin D supplementation (with or without calcium [Ca]) have shown that vitamin D reduced the risk of hip and any fractures¹³. In another meta-analysis, active vitamin D preparations significantly reduced the incidence

¹Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. ²Department of Health Administration and Policy, Tohoku University School of Medicine, 2-1 Seiryō-Machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. ³Department of Hygiene and Public Health, Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan. ⁴Department of Orthopedic Surgery, Asahi General Hospital, 477 Tomari, Asahimachi, Shimo-Nikawa-gun, Toyama 939-0798, Japan. ⁵Department of Regulatory Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 193-0392, Japan. ⁶Okimoto Clinic, 185-4 Kubi, Yutaka-machi, Kure, Hiroshima 734-0304, Japan. ⁷Kindai University Faculty of Medicine, 377-2 Oono-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. ⁸National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Kindai University Faculty of Medicine, 377-2 Oono-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. ✉email: suogawa@m.u-tokyo.ac.jp

of vertebral and nonvertebral fractures compared with natural vitamin D supplementation¹⁴. Another systematic review reported that alfacalcidol (ALF) and calcitriol (CAL) significantly reduced the incidence of nonvertebral fractures, and subgroup analyses demonstrated a significant reduction of the incidence of vertebral fractures with ALF, but not with CAL¹⁵. Eldecacitol (ELD), a derivative of CAL, is a more potent inhibitor of bone resorption, having potent bone mass-increasing effects¹⁶. Some studies have shown that ELD is more effective than ALF in increasing BMD and preventing bone fractures^{17–19}. In a meta-analysis, ELD significantly increased lumbar BMD, total hip BMD, and femoral neck BMD and significantly reduced the incidence of vertebral fractures compared with ALF, but did not reduce the incidence of nonvertebral fractures²⁰.

Vitamin D might also play an important role in skeletal muscles. In animal experiments, myocyte-specific VDR knockout mice showed decreased expressions of genes related to cell cycle progression and Ca regulation in skeletal muscles and reduced lean mass, grip strength, and running speed²¹. In humans, vitamin D has been reported to prevent falls. In a meta-analysis, supplemental vitamin D and active forms of vitamin D reduced falls in older people²². Vitamin D3 reduced the rate of falls in a randomized-controlled trial (RCT) of postmenopausal women aged ≤ 65 years with osteoporosis²³. These effects of preventing falls might be involved in the reduction of fracture risk.

Although vitamin D supplementation and active forms of vitamin D have been suggested to increase BMD and reduce the risk of vertebral and nonvertebral fractures, few studies have focused on the prevention of hip fractures.

In this study, we examined the association between the presence or absence of vitamin D prescriptions and the incidence of osteoporosis-related bone fractures, using data from the National Database in Japan.

Methods

Herein, “vitamin D” refers to ALF, CAL, and ELD. “Osteoporosis-related fractures” refers to hip, vertebral, and radial fractures.

Data source. The Japanese health insurance system are described elsewhere²⁴. Japan has a universal coverage of social health insurance and Japanese inhabitants are obliged to join one of the three sub-systems; National Health Insurance (for self-employment), Society Health Insurance (for employee) and Special scheme for the aged (75 years old or over). At the end of each month, medical facilities send sets of claims for reimbursement to insurers via the review organization. For that purpose, medical facilities use a special computer system, in which all procedures, drugs and devices for reimbursement are registered for each patient by daily basis. There is a standard code for each of all procedures, drugs and devices.

The Japanese Ministry of Health, Labor and Welfare (MHLW) have developed the National Database of Health Insurance Claims and Specific Health Checkups of Japan since 2008²⁴. The National Database (NDB) registers all healthcare insurance claims and detailed datasets at the individual patient base: that is, the database covers all the data of the Japanese inhabitants. The NDB contains the detailed information such as insurer's code, insured ID number, diagnoses, age, sex, date of consultation for out-patient service, procedures, and drugs provided with information of date, etc. More than 1,700 million records are registered into the NDB every year. The NDB can be used for research with the approval by the MHLW.

Study design. This study is a retrospective cohort study using data from the NDB. ID numbers are generated by an encrypting function to make data anonymous but combinable for the same patient. The protocol of this study was approved by the MHLW.

Patients and data extraction. This study used NDB data from March 2012 to March 2019. Patients for whom 3.5 years of data were available were included in the analysis if they met the inclusion and exclusion criteria (i.e., no one died during the period of 3.5 years).

Data of patients who meet all of the following inclusion criteria were used for analysis in this study: (1) aged > 40 years at the date of entry, (2) diagnosed with osteoporosis as of the date of entry, (3) have never been prescribed vitamin D in the 6 months before the date of entry, and (4) it is known whether they are newly diagnosed as osteoporosis-related fractures or not within 3 years from the date of entry.

Patients were excluded if they met any of the following exclusion criteria: (1) have been prescribed anything other than osteoporosis medications at least once between the date of entry and the end of follow-up, (2) are prescribed medications for more than 90 days at one time (because the maximum number of drugs that can be prescribed per day is 90 in Japan), and (3) developed an osteoporosis-related fracture on the date of entry or within 90 days of the date of entry.

According to these criteria, the following data of the patients were extracted from the NDB: anonymized ID; date of entry; date 1095 days after the date of entry; age at the date of entry; sex; number of ALF, CAL, or ELD prescription days from entry to day 90, from day 91 to day 180, from day 181 to day 365, from day 366 to day 730, and from day 731 to day 1095 after entry; presence or absence of hip, vertebral, or radial fractures from entry to day 1095; and date of diagnosis of such fractures. Patients who met the inclusion and exclusion criteria and had no missing data for 3 years after entry were analyzed. The date of entry ranged from September 2012 to March 2016. There was no entry from March 2012 to August 2012 because data from this period were retrieved only to determine whether patients met the inclusion criteria 3.

The end of follow-up was defined as one of the following: (1) the first date within 3 years of the date of entry, when a new osteoporosis-related fracture was diagnosed, or (2) the date exactly 1095 days (= 3 years) have elapsed since the date of entry (if the patient did not develop a new osteoporosis-related fracture). The last follow-up was completed in March 2019.

The drug and diagnosis codes used to extract data from the NDB are provided as Supplementary File 1. Each drug has a 9-digit code, and each disease has a 7-digit Japanese Standard Disease Code (JSDC). If a patient data had one of the JSDCs of osteoporosis-related fractures and the registration date of the JDCS during the follow-up, the patient was regarded to have developed a new osteoporosis-related fracture on the date.

Patient selection based on the medication possession ratio (MPR). The MPR was used to quantify medication adherence. MPR is the sum of days' supply divided by the number of days in a period²⁵. To ensure the effects of vitamin D, only those who maintained an MPR above a certain level throughout the follow-up period were considered in the treatment group. The number of tracking days from the date of entry was divided into five periods: entry to day 90, day 91 to day 180, day 181 to day 365, day 366 to day 730, and day 731 to day 1095. Untreated patients were defined as "those who were never prescribed vitamin D from the date of entry to the end of follow-up". Treated patients were defined as "those with $MPR \geq 0.5$ for all the periods before the end of follow-up". Patients who did not fit into either group were excluded.

Propensity score (PS) matching. We performed one-to-one PS matching between the untreated and treated patients^{26–28}. To estimate PS, we employed a logistic regression model, where the covariates included age, sex, prescriptions of osteoporosis medications (e.g., BPs, PTH, menatetrenone, and SERMs) during the 6 months before entry, and incident fractures (hips, vertebrae, and radius) during the six months before entry, and place of residence (47 prefectures); the outcome was untreated (coded as 0) or treated (coded as 1). We calculated the C-statistic to assess the model's discriminatory ability. Using PS estimates, we performed nearest-neighbor matching without replacement, setting the caliper at 0.2 times the standard deviation of the PS estimates²⁷. This yielded matched pairs, and the PS-matched control and treatment groups were established.

The incidence rate of osteoporosis-related fractures was compared between the PS-matched control and treatment groups. The rate was also compared by fracture sites.

Subgroup analysis by the type of vitamin D. The patients in the PS-matched treatment group were stratified based on the type of prescribed vitamin D: the ALF, CAL, ELD groups, and patients prescribed more than one type of vitamin D during follow-up were included in the "mix" group. As a subanalysis, fracture incidence by type of vitamin D was compared in the treatment group. It was also compared with the control group.

Statistical analyses. Data analysis was performed using R 3.3.3 software (R Foundation for Statistical Computing, Vienna, Austria), and $p < 0.001^*$ was considered significant. The incidence rates of fractures were analyzed using the Kaplan–Meier curve and Log-rank test. The Pearson χ^2 test was used for categorical variables, with two-sided.

To evaluate factors on the incidence of new fractures, a Cox regression analysis was performed. We set age, sex, prescriptions before entry, incident fractures before entry, and place of residence as risk-adjusting covariates, the treatment as explanatory variable, and the development of osteoporosis-related fractures as the dependent variable (fracture no = 0, fracture yes = 1).

Ethics approval and consent to participate. The study protocol was approved by the Institutional Review Board of the Graduate School of Medicine, The University of Tokyo (Approval Number: 2020291NI), as well as the MHLW. All methods were performed in accordance with the relevant regulations and guidelines. The data in this study were completely anonymous; therefore, the need of informed consent was waived by the Institutional Review Board of the Graduate School of Medicine, The University of Tokyo.

Results

The patient selection process is illustrated in Fig. 1. From the patient data from March 2012 to March 2019, a total of 725,379 patients who met the inclusion and exclusion criteria were extracted. Among these patients, 4450 who developed fractures within 90 days of entry were excluded, leaving 720,929 patients. After the patient selection based on the calculated MPR, untreated patients numbered 422,454, and treated patients numbered 169,774. The characteristic of the untreated and treated patients are presented in Table 1, and their place of residence (prefectures) is provided in Supplementary Table 1. Compared to untreated patients, treated patients were significantly older, had a higher proportion of men, had a lower proportion of prescriptions of other osteoporosis drugs (BPs, PTH, Menatetrenone, and SERMs) before entry, and had a higher incidence of fractures (hips and vertebrae) before entry. During the follow-up, 26,845 (6.4%) untreated patients developed fractures (hip, 4008 cases; vertebrae, 20,197 cases; radius, 2640 cases), while 8,398 (4.9%) treated patients developed fractures (hip, 687 cases; vertebrae, 6730 cases; radius, 981 cases). The incidence of all fractures was significantly lower in treated patients compared to untreated patients ($p < 0.001^*$).

In the logistic regression model, the variance inflation factors were below 5 in all the covariates, indicating no multicollinearity. The C-statistic was 0.7245. After performing PS matching, the PS-matched control group ($n = 105,041$) and the PS-matched treatment group ($n = 105,041$) were established. The characteristics of the groups are shown in Table 1, and the patients' place of residence (prefectures) is provided in Supplementary Table 1. After PS matching, the standardized mean difference (SMD) between the two groups were < 0.1 in all the variables, suggesting that the distributions of patient background variables were well balanced. Incidentally, within the section of incident fractures before entry in Table 1, the specific quantities of hip, vertebra, and radius fractures are not displayed; solely the numbers in total are provided. This practice is implemented to comply




Figure 1. Flow diagram for the patient selection and PS matching. The chart shows how the control group patients were extracted from the NDB. Characteristics of the untreated and treated patients, the PS-matched control and treatment groups are described in Table 1.

	Before PS matching				After PS matching		
	Untreated patients	Treated patients	SMD	p-value	PS-matched control group	PS-matched treatment group	SMD
n	422,454	169,774			105,041	105,041	
Age	73.4 ± 9.7	73.7 ± 9.2	0.033	< 0.001*	73.4 ± 9.5	73.4 ± 8.6	0.004
Sex							
Men	18,544 (4.4%)	8465 (5.0%)	0.028	< 0.001*	2456 (2.3%)	2373 (2.3%)	0.005
Women	403,910 (95.6%)	161,309 (95.0%)			102,585 (97.7%)	102,668 (97.7%)	
Prescriptions before entry							
BPs	182,630 (43.2%)	48,927 (28.8%)	0.304	< 0.001*	48,401 (46.1%)	48,927 (46.6%)	0.010
PTH	36,537 (8.6%)	4449 (2.6%)	0.264	< 0.001*	4753 (4.5%)	4449 (4.2%)	0.014
Menatetrenone	11,705 (2.8%)	2372 (1.4%)	0.096	< 0.001*	3418 (3.3%)	2372 (2.3%)	0.061
SERMs	204,561 (48.4%)	53,656 (31.6%)	0.348	< 0.001*	52,831 (50.3%)	53,656 (51.1%)	0.016
Incident fractures before entry							
Hip	5476 (1.3%) in total	3143 (1.9%) in total	0.022	< 0.001*	1913 (1.8%) in total	1709 (1.6%) in total	0.010
Vertebra			0.039	< 0.001*			0.012
Radius			0.003	0.499			< 0.001

Table 1. The characteristic of the patients before and after the PS matching. Age is expressed as mean ± standard deviation. To comply with the NDB regulations, only the total number of three types of fractures are presented in the incident fractures before entry. SMD standardized mean difference. * $p < 0.001$ is considered significant.

with the privacy policy of the NDB that stipulates that the presentation of data is prohibited when the number of fracture events is below ten.

The incidence rates of all osteoporosis-related fractures during the follow-up period were 6.25% (6562 cases) in the PS-matched control group and 5.69% (5974 cases) in the PS-matched treatment group. The Kaplan–Meier curve is presented in Fig. 2. The log-rank test showed that the fracture rate was significantly lower in the PS-matched treatment group ($p < 0.001^*$).




Figure 2. Cumulative incidence of total fractures in the PS-matched control and treatment groups. The solid line represents the PS-matched control group, and the dashed line represents the PS-matched treatment group.

To examine whether the treatment independently affected the development of fractures, we conducted a Cox regression analysis in the PS-matched control and treatment groups. The log minus log plots of the control and treatment groups were approximately parallel, suggesting the validity of proportional hazards assumption. After adjustments of age, sex, prescriptions before entry, incident fractures before entry, and place of residence, the treatment significantly reduced the incidence of new fractures (HR 0.936 [95% confidence interval (95% CI) 0.904–0.970], $p < 0.001^*$) (Table 2). The HRs by the patients' place of residence are provided in Supplementary Table 2.

Fracture rates were compared by site. The site-specific fracture incidence rates were 0.89% (938 cases) and 0.42% (441 cases) (hip), 4.71% (4,952 cases) and 4.65% (4,883 cases) (vertebrae), and 0.64% (672 cases) and 0.62% (650 cases) (radius) (Fig. 3). The log-rank test showed a significant difference only for the hips ($p < 0.001^*$) and no significant difference for the vertebrae and radius ($p = 0.4149$ and $p = 0.5182$, respectively).

Subgroup analyses were performed for each type of administered vitamin D. The ALF, CAL, ELD, and mix groups consisted of 16,656, 962, 86, 494, and 929 patients, respectively. The fracture incidence of these groups was compared with that of the PS-matched control group in the main analysis ($n = 105,041$). The Kaplan–Meier curve and the total fracture rate of these five groups are shown in Fig. 4. Total fracture rates were 6.25% (6562 cases), 4.73% (788 cases), 5.61% (54 cases), 5.87% (5079 cases), and 5.71% (53 cases) in the control, ALF, CAL, ELD, and mix groups, respectively. The ALF and ELD groups demonstrated significantly lower fracture rates compared to the control group, and the ALF group demonstrated significantly lower fracture rate than the ELD group ($p < 0.001^*$). No significant difference was observed between the other groups. Table 3 presents the

Variable	HR for fractures [95% CI]	p -value
Age	1.062 [1.060–1.064]	< 0.001*
Sex (women = 1)	0.914 [0.824–1.015]	0.092
Prescriptions before entry		
BPs	1.153 [1.075–1.237]	< 0.001*
PTH	1.734 [1.605–1.872]	< 0.001*
Menatretrenone	1.167 [1.047–1.300]	0.005
SERMs	1.089 [1.014–1.170]	0.019
Incident fractures before entry		
Hip	1.054 [0.783–1.418]	0.731
Vertebra	1.888 [1.723–2.065]	< 0.001*
Radius	0.000 [0.000–over 10^{10}]	0.960
Treatment	0.936 [0.904–0.970]	< 0.001*

Table 2. Cox regression analysis to evaluate factors on the incidence of fractures. HRs by the patients' place of residence (prefecture) are provided in Supplementary Table 2. CI confidence interval. * $p < 0.001$ is considered significant.




Figure 3. Cumulative incidence of fractures by site. * $p < 0.001$ is considered significant.




Figure 4. Cumulative incidence of total fractures by the type of vitamin D. * $p < 0.001$ is considered significant.

	ALF group	CAL group	ELD group	Mix group	p-value
n	16,656	962	86,494	929	
Age	75.5 ± 8.6	75.4 ± 8.9	73.0 ± 8.6	76.9 ± 9.0	< 0.001*
Sex					
Men	393 (2.4%)	27 (2.8%)	1922 (2.2%)	31 (3.3%)	0.058
Women	16,263 (97.6%)	935 (97.2%)	84,572 (97.8%)	898 (96.7%)	
Prescriptions before entry					
BPs	6043 (36.3%)	353 (36.7%)	42,165 (48.7%)	366 (39.4%)	< 0.001*
PTH	882 (5.3%)	26 (2.7%)	3469 (4.0%)	72 (7.8%)	< 0.001*
Menatetrenone	690 (4.1%)	68 (7.1%)	1566 (1.8%)	48 (5.2%)	< 0.001*
SERMs	8765 (52.6%)	509 (52.9%)	43,909 (50.8%)	473 (50.9%)	< 0.001*
Incident fractures before entry (hip + vertebra + radius)	484 (2.9%)	18 (1.9%)	1152 (1.3%)	55 (5.9%)	< 0.001*

Table 3. Subgroups of the PS-matched treatment group by the type of vitamin D. Age is expressed as mean ± standard deviation. SMD standardized mean difference. * $p < 0.001$ is considered significant.

characteristics of the subgroups. In the ELD group, the age was significantly younger, the proportion of patients prescribed BPs before entry was significantly higher, and the proportion of patients prescribed PTH, menatetrenone, and SERMs was significantly lower compared to the ALF group. Additionally, the proportion of patients who experienced hip and vertebral fractures before entry was significantly lower ($p < 0.001^*$). After controlling for age, sex, prescriptions before entry, incident fractures before entry, and place of residence using a Cox regression

analysis, the HRs for the incidence of new fractures in relation to the type of vitamin D are presented in Table 4. The HR showed a significant reduction only in the ALF group (HR 0.676 [95% CI 0.628–0.728]).

Discussion

This study demonstrated an association between vitamin D and a decrease in fracture incidence using PS matching. By site, the incidence of hip fractures significantly decreased, but vertebral and radius fractures did not show a significant reduction. The decrease in total fractures was primarily due to the decrease in hip fractures. These results are consistent with previous studies showing that vitamin D reduced the incidence of fractures. Since all national data are registered in the NDB, this study is considered free of selection bias.

In subgroup analyses, both the ELD and ALF groups had a lower incidence rate of total fractures than the PS-matched control group. However, the incidence rate of fractures was significantly higher in the ELD group compared to the ALF group (Fig. 4). Furthermore, the HRs for new fractures were reduced only in the ALF group after the Cox regression analysis (Table 4). This finding is inconsistent with a meta-analysis showing that ELD had a higher effect on bone density increase and fracture prevention than ALF²⁰. This is possible because the present study is not an RCT but a retrospective study. Although PS matching partially adjusted for background differences between the control and treatment groups, patient characteristics differed between the ALF and ELD groups. For example, the average age of the ELD group was significantly lower than that of the ALF and CAL groups, although age was positively related to the incidence of fractures (Table 3). This suggests that the characteristics of patients administered ELD might be different from that of patients administered ALF or CAL. ELD was more recently available than ALF and CAL, is reported to be more effective in the treatment of osteoporosis^{17–20}, thus might have been administered to patients at particularly high risk of fractures. In addition, inconsistent with previous studies that suggested that vitamin D analogs reduced vertebral fractures^{14,15}, vitamin D did not reduce the risk of vertebral fractures (Fig. 3), which might be considered a limitation of PS matching.

While active forms of vitamin D reduced the risk of developing fractures compared with vitamin D supplementation¹⁴, vitamin D supplementation could reduce the fracture risk, especially in combination with calcium¹³. In Japan, vitamin D supplements are available over-the-counter, but active forms of vitamin D are not. Patients in the control group are guaranteed not to receive active forms of vitamin D, but they might have been taking vitamin D supplements, which could have affected the results.

In the subanalysis, the prescription of CAL was not associated with a lower incidence of fractures. Only 962 patients in the PS-matched treatment group were prescribed CAL, suggesting that CAL is rarely prescribed in Japan. CAL did not reduce the incidence of vertebral fractures¹⁵, while it increased bone mineral density at the lumbar spine in osteoporotic patients with vitamin D deficiency²⁹. The incidence of fractures in the CAL group was 5.61%, which was slightly lower than the 5.71% in the ELD group, suggesting the statistical power was insufficient.

Although treatment of osteoporosis is important to prevent the initial hip fracture, older people may have difficulty using other drugs (e.g., BPs) due to low activities of daily living, comorbidities, and social circumstances, and active vitamin D could be a treatment option.

This study has several limitations. Firstly, although we performed PS matching, it was not possible to adjust for all patients background. We adjusted for age, sex, prescriptions of osteoporosis medications before entry, incident fractures before entry, and regions of the patients, but could not adjust for other possible confounders that could affect the risk of fractures. For instance, BMD data is not included in the NDB, and information on other confounding factors (e.g., activities of daily living, exercise habits, dietary habits, body mass index, socioeconomic status, living situation, etc.) is also unavailable from the NDB, and their effects could not be taken into account. Secondly, we excluded patients who were prescribed non-osteoporotic drugs. This was intended to examine the association between vitamin D and the incidence of fractures after excluding the possible influence of other diseases as much as possible. However, since the remaining study population could be different from older people in general (often characterized by multimorbidity and polypharmacy), results of the present study might not be applicable to them. Furthermore, not being on medication does not necessarily mean not having the diseases. We could not consider the possible effects of comorbidities and medical histories on the risk of developing new fractures (e.g., diabetes mellitus, rheumatoid arthritis, etc.). However, due to the restrictions of the NDB, this was the limit of the patient information that could be obtained. Finally, data of the patients who died within 3 years of entry were not extracted from the beginning, which might have affected the result.

Variable	HR for fractures [95% CI]	p-value
The type of vitamin D		
ALF	0.676 [0.628–0.728]	< 0.001*
CAL	0.817 [0.625–1.068]	0.139
ELD	1.003 [0.967–1.040]	0.881
Mix	0.692 [0.528–0.907]	0.008

Table 4. The HRs for the incidence of fractures in relation to the type of vitamin D. Age, sex, prescriptions before entry, incident fractures before entry, and place of residence (prefectures) were adjusted (data not shown). *CI* confidence interval. * $p < 0.001$ is considered significant.

Due to these major limitations and the fact that this is not an RCT, the causal relationship between vitamin D administration and reduced incidence of fractures cannot be assessed.

In summary, the results of this study suggest that vitamin D was associated with lower incidence of hip fractures. Reevaluation of the usefulness of vitamin D may lead to the development of osteoporosis treatment for older people who require individualized care.

Data availability

The data that support the findings of this study are available from the MHLW but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from Sumito Ogawa upon reasonable request and with permission of the MHLW.

Received: 8 October 2022; Accepted: 7 August 2023

Published online: 09 August 2023

References

- Reid, I. R. & Billington, E. O. Drug therapy for osteoporosis in older adults. *Lancet* **399**, 1080–1092. [https://doi.org/10.1016/s0140-6736\(21\)02646-5](https://doi.org/10.1016/s0140-6736(21)02646-5) (2022).
- Salari, N. *et al.* Global prevalence of osteoporosis among the world older adults: A comprehensive systematic review and meta-analysis. *J. Orthop. Surg. Res.* **16**, 669. <https://doi.org/10.1186/s13018-021-02821-8> (2021).
- Parkkari, J. *et al.* Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: A prospective controlled hip fracture study with 206 consecutive patients. *Calcif. Tissue Int.* **65**, 183–187. <https://doi.org/10.1007/s002239900679> (1999).
- Palvanen, M. *et al.* The injury mechanisms of osteoporotic upper extremity fractures among older adults: A controlled study of 287 consecutive patients and their 108 controls. *Osteoporos. Int.* **11**, 822–831. <https://doi.org/10.1007/s001980070040> (2000).
- Brenneman, S. K., Barrett-Connor, E., Sajjan, S., Markson, L. E. & Siris, E. S. Impact of recent fracture on health-related quality of life in postmenopausal women. *J. Bone Miner. Res.* **21**, 809–816. <https://doi.org/10.1359/jbmr.060301> (2006).
- Leibson, C. L., Tosteson, A. N., Gabriel, S. E., Ransom, J. E. & Melton, L. J. Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study. *J. Am. Geriatr. Soc.* **50**, 1644–1650. <https://doi.org/10.1046/j.1532-5415.2002.50455.x> (2002).
- Bliuc, D., Nguyen, N. D., Nguyen, T. V., Eisman, J. A. & Center, J. R. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. *J. Bone Miner. Res.* **28**, 2317–2324. <https://doi.org/10.1002/jbmr.1968> (2013).
- Balasubramanian, A. *et al.* Risk of subsequent fracture after prior fracture among older women. *Osteoporos. Int.* **30**, 79–92. <https://doi.org/10.1007/s00198-018-4732-1> (2019).
- Barceló, M., Torres, O. H., Mascaró, J. & Casademont, J. Hip fracture and mortality: Study of specific causes of death and risk factors. *Arch. Osteoporos.* **16**, 15. <https://doi.org/10.1007/s11657-020-00873-7> (2021).
- Gallagher, J. C., Fowler, S. E., Detter, J. R. & Sherman, S. S. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. *J. Clin. Endocrinol. Metab.* **86**, 3618–3628. <https://doi.org/10.1210/clinem.86.8.7703> (2001).
- Shikari, M. *et al.* Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: A placebo-controlled, double-blind prospective study. *Endocr. J.* **43**, 211–220. <https://doi.org/10.1507/endocrj.43.211> (1996).
- Habibi Ghahfarrokhi, S., Mohammadian-Hafshejani, A., Sherwin, C. M. T. & Heidari-Soureshjani, S. Relationship between serum vitamin D and hip fracture in the elderly: A systematic review and meta-analysis. *J. Bone Miner. Metab.* <https://doi.org/10.1007/s00774-022-01333-7> (2022).
- Chakhtoura, M. *et al.* Vitamin D supplementation and fractures in adults: A systematic umbrella review of meta-analyses of controlled trials. *J. Clin. Endocrinol. Metab.* **107**, 882–898. <https://doi.org/10.1210/clinem/dgab742> (2022).
- Richy, F. *et al.* Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. *Calcif. Tissue Int.* **76**, 176–186. <https://doi.org/10.1007/s00223-004-0005-4> (2005).
- O'Donnell, S., Moher, D., Thomas, K., Hanley, D. A. & Cranney, A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. *J. Bone Miner. Metab.* **26**, 531–542. <https://doi.org/10.1007/s00774-008-0868-y> (2008).
- Uchiyama, Y. *et al.* ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. *Bone* **30**, 582–588. [https://doi.org/10.1016/s8756-3282\(02\)00682-8](https://doi.org/10.1016/s8756-3282(02)00682-8) (2002).
- Matsumoto, T. *et al.* A new active vitamin D3 analog, eldecacitol, prevents the risk of osteoporotic fractures—A randomized, active comparator, double-blind study. *Bone* **49**, 605–612. <https://doi.org/10.1016/j.bone.2011.07.011> (2011).
- Hagino, H. *et al.* Eldecacitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. *J. Bone Miner. Metab.* **31**, 183–189. <https://doi.org/10.1007/s00774-012-0397-6> (2013).
- Nakamura, T., Takano, T., Fukunaga, M., Shiraki, M. & Matsumoto, T. Eldecacitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. *J. Bone Miner. Metab.* **31**, 417–422. <https://doi.org/10.1007/s00774-012-0418-5> (2013).
- Cui, L., Xia, W., Yu, C., Dong, S. & Pei, Y. Overview of the clinical efficacy and safety of eldecacitol for the treatment of osteoporosis. *Arch. Osteoporos.* **17**, 74. <https://doi.org/10.1007/s11657-022-01071-3> (2022).
- Girgis, C. M. *et al.* Mice with myocyte deletion of vitamin D receptor have sarcopenia and impaired muscle function. *J. Cachexia Sarcopenia Muscle* **10**, 1228–1240. <https://doi.org/10.1002/jcsm.12460> (2019).
- Bischoff-Ferrari, H. A. *et al.* Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomised controlled trials. *BMJ* **339**, b3692. <https://doi.org/10.1136/bmj.b3692> (2009).
- Cangussu, L. M. *et al.* Effect of isolated vitamin D supplementation on the rate of falls and postural balance in postmenopausal women fallers: A randomized, double-blind, placebo-controlled trial. *Menopause* **23**, 267–274. <https://doi.org/10.1097/gme.0000000000000525> (2016).
- Matsuda, S. & Fujimori, K. The claim database in Japan. *Asian Pac. J. Dis. Manag.* **6**, 55–59. <https://doi.org/10.7223/apjdm.6.55> (2012).
- Canfield, S. L. *et al.* Navigating the wild west of medication adherence reporting in specialty pharmacy. *J. Manag. Care Spec. Pharm.* **25**, 1073–1077. <https://doi.org/10.18553/jmcp.2019.25.10.1073> (2019).
- Yasunaga, H. *et al.* Outcomes after laparoscopic or open distal gastrectomy for early-stage gastric cancer: A propensity-matched analysis. *Ann. Surg.* **257**, 640–646. <https://doi.org/10.1097/SLA.0b013e31826fd541> (2013).
- Hosoi, T. *et al.* Association between comprehensive geriatric assessment and short-term outcomes among older adult patients with stroke: A nationwide retrospective cohort study using propensity score and instrumental variable methods. *EClinicalMedicine* **23**, 100411. <https://doi.org/10.1016/j.eclinm.2020.100411> (2020).
- Ohbe, H., Jo, T., Matsui, H., Fushimi, K. & Yasunaga, H. Effect of Daikenchuto for mechanically ventilated patients with enteral feeding intolerance: A propensity score-matched analysis using a nationwide administrative inpatient database. *J. Parenter. Enteral Nutr.* **45**, 1703–1713. <https://doi.org/10.1002/jpen.2076> (2021).

29. Tanakol, R., Gül, N., Üzüm, A. K. & Aral, F. Calcitriol treatment in patients with low vitamin D levels. *Arch. Osteoporos.* **13**, 114. <https://doi.org/10.1007/s11657-018-0529-2> (2018).

Acknowledgements

This study was funded by the MHLW.

Author contributions

M.Y. and S.O. designed the study. K.F. acquired the data. M.Y., T.H., S.M. and S.O. conducted statistical analysis. All authors contributed to the interpretation of the data. M.Y. drafted the manuscript and the other authors revised it for intellectual content. All authors approved the final draft of the manuscript for submission. M.A. supervised the study. All authors had full access to all the data (including statistical reports and tables) in the study and S.O. had final responsibility for the decision to submit for publication.

Funding

Financial support for the present study was provided by a 52nd Taiju Life Social Welfare Foundation Medical Research Grant 2019, a Japan Osteoporosis Foundation Grant for Bone Research 2019, and a 28th Pfizer Health Research Grant 2019. The funding bodies had no role in designing the study, collecting, analyzing, or interpreting the data, writing the manuscript, or deciding where to submit the manuscript for publication.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-40259-6>.

Correspondence and requests for materials should be addressed to S.O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023